✦ LIBER ✦

A pilot study using nabilone for symptomatic treatment in Huntington's disease

✍ Scribed by Adrienne Curtis; Ian Mitchell; Smitaa Patel; Natalie Ives; Hugh Rickards

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 125 KB
Volume: 24
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.22809

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Pilot study of nabilone in Huntington's disease (HD). Double‐blind, placebo‐controlled, cross‐over study of nabilone versus placebo. Primary outcome, Unified Huntington's Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = 22), or placebo followed by nabilone (n = 22). Recruiting was straightforward. Nabilone safe and well tolerated, no psychotic episodes. Assessment of either dose of nabilone versus placebo showed a treatment difference of 0.86 (95% CI: −1.8 to 3.52) for total motor score; 1.68 (95% CI: 0.44 to 2.92) for chorea; 3.57 (95% CI: −3.41 to 10.55) for UHDRS cognition; 4.01 (95% CI: −0.11 to 8.13) for UHDRS behavior, and 6.43 (95% CI: 0.2 to 12.66) for the NPI. Larger longer RCT of nabilone in HD is feasible and warranted. © 2009 Movement Disorder Society

📜 SIMILAR VOLUMES

Minocycline in Huntington's disease: A p

Minocycline in Huntington's disease: A pilot study

✍ Madhavi Thomas; Tetsuo Ashizawa; Joseph Jankovic 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB 👁 1 views

## Abstract Minocycline is a caspase inhibitor, decreases inducible nitric oxide synthase (iNOS), and has been shown to delay disease progression in the mouse model R6/2 of Huntington's disease (HD). This safety and tolerability study included 30 patients with HD who were given minocycline over a 6

Open-label pilot study of levetiracetam

Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease

✍ Theresa A. Zesiewicz; Kelly L. Sullivan; Robert A. Hauser; Juan Sanchez-Ramos 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 1 views

## Abstract The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open‐label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day fo

Symptomatic relief from treatment-induce

Symptomatic relief from treatment-induced psychosis in Parkinson's disease: An open-label pilot study with remoxipride

✍ Dr. Tilak Mendis; Erich Mohr; Amanda George; Ilene N. Rusk; Peggy Gray; J. David 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 320 KB 👁 1 views

## Abstract Current treatment strategies for levodopa‐induced psychosis in Parkinson's disease have had limited success. Remoxipride, a selective D~2~ receptor antagonist, was administered in an open label pilot study to seven parkinsonian patients exhibiting thought disorder. Symptoms improved sig

Atomoxetine for the treatment of executi

Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open-label study

✍ Laura Marsh; Kevin Biglan; Melissa Gerstenhaber; James R. Williams 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 321 KB 👁 1 views

## Abstract Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention defi

Cognitive-behavioral therapy for depress

Cognitive-behavioral therapy for depression in Parkinson's disease: A pilot study

✍ Roseanne DeFronzo Dobkin; Lesley A. Allen; Matthew Menza 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

## Abstract The present study was conducted to examine the feasibility and effect of an individual cognitive‐behavioral treatment (CBT) for depression that was modified to meet the unique needs of the PD patient and incorporated a separate social support intervention for caregivers. Fifteen PD pati

Evaluation of acupuncture in the treatme

Evaluation of acupuncture in the treatment of Parkinson's disease: A double-blind pilot study

✍ Adrian Cristian; Meredith Katz; Eileen Cutrone; Ruth H. Walker 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB 👁 1 views

## Abstract As many as 40% of patients with Parkinson's disease (PD) use some form of complementary medicine during the course of their illness, and many try acupuncture. One nonblinded study of the effects of acupuncture in PD suggested that it might be helpful for some aspects of PD. We performed